Journal ArticleDOI
Cancer survival corrected for heterogeneity in patient withdrawal.
Reads0
Chats0
TLDR
A method based on the concept of an 'expected life table' is proposed for removal of the bias and it is suggested that the practical performance of the proposed method is better than that of other alternatives, even when the relative survival rates in the subgroups are not equal.Abstract:
Survival from cancer over a certain time period is often measured by the 'relative survival rate'. This is the ratio of the observed survival rate in the group of patients to the survival rate expected in a group of people in the general population, who are similar to the patients with respect to all of the possible factors affecting survival at the beginning of the period, except for the disease under study. When patterns of patient withdrawal differ for a number of subgroups of patients with equal relative survival rates, the current method of derivation of the relative survival rate is biased. A method based on the concept of an 'expected life table' is proposed for removal of the bias. Examples based on material from the Finnish Cancer Registry suggest that the practical performance of the proposed method is better than that of other alternatives, even when the relative survival rates in the subgroups are not equal.read more
Citations
More filters
Journal ArticleDOI
Cancer survival in five continents: a worldwide population-based study (CONCORD)
Michel P Coleman,Manuela Quaresma,F Berrino,Jean-Michel Lutz,Roberta De Angelis,Riccardo Capocaccia,Paolo Baili,Bernard Rachet,Gemma Gatta,Timo Hakulinen,Andrea Micheli,Milena Sant,Hannah K. Weir,J. Mark Elwood,Hideaki Tsukuma,Sergio Koifman,Gulnar Azevedo e Silva,Silvia Francisci,Mariano Santaquilani,Arduino Verdecchia,Hans H. Storm,John L. Young +21 more
TL;DR: This is, to the authors' knowledge, the first worldwide analysis of cancer survival, with standard quality-control procedures and identical analytic methods for all datasets, and should eventually facilitate joint assessment of international trends in incidence, survival, and mortality as indicators of cancer control.
Journal ArticleDOI
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.
Francisco Cervantes,Brigitte Dupriez,Arturo Pereira,Francesco Passamonti,John T. Reilly,Enrica Morra,Alessandro M. Vannucchi,Ruben A. Mesa,Jean Loup Demory,Giovanni Barosi,Elisa Rumi,Ayalew Tefferi +11 more
TL;DR: In 409 patients with assessable metaphases, cytogenetic abnormalities were associated with shorter survival, but their independent contribution to prognosis was restricted to patients in the intermediate-risk groups.
Journal ArticleDOI
Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data.
Arduino Verdecchia,Silvia Francisci,Hermann Brenner,Gemma Gatta,Andrea Micheli,Lucia Mangone,Ian Kunkler +6 more
TL;DR: Age-adjusted 5-year period survival improved for patients diagnosed in 2000-02, especially for patients with colorectal, breast, prostate, and thyroid cancer, Hodgkin's disease, and non-Hodgkin lymphoma, although, patients in eastern European had the highest improvement in survival for major cancer sites during 1991-2002.
Journal ArticleDOI
EUROCARE-3: survival of cancer patients diagnosed 1990–94—results and commentary
Milena Sant,Tiiu Aareleid,Franco Berrino,M Bielska Lasota,P. M. Carli,Jean Faivre,Pascale Grosclaude,G. Hedelin,T Matsuda,Henrik Møller,T. Möller,Arduino Verdecchia,Riccardo Capocaccia,Gemma Gatta,Andrea Micheli,Mariano Santaquilani,Paolo Roazzi,D Lisi +17 more
TL;DR: EUROCARE-3 as mentioned in this paper analyzed the survival of 1815584 adult cancer patients diagnosed from 1990 to 1994 in 22 European countries and found that survival was highest in northern Europe (Sweden, Norway, Finland and Iceland), and fairly good in central-southern Europe (France, Switzerland, Austria and Spain).
Journal ArticleDOI
EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary.
Milena Sant,Claudia Allemani,Mariano Santaquilani,Arnold Knijn,Francesca Marchesi,Riccardo Capocaccia +5 more
TL;DR: Survival for most solid cancers, whose prognosis depends largely on stage at diagnosis, was highest in Finland, Sweden, Norway and Iceland, lower in the UK and Denmark, and lowest in the Czech Republic, Poland and Slovenia.